Hydronidone
- Generic Name
- Hydronidone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO2
- CAS Number
- 851518-71-3
- Unique Ingredient Identifier
- RXQ128313W
- Background
Hydronidone has antifibrotic activity.
- Indication
Investigated for use/treatment in liver disease.
- Associated Conditions
- -
- Associated Therapies
- -
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating ...
Gyre Therapeutics announces completion of F351 Phase 3 trial for CHB-associated liver fibrosis in China, with topline data expected by Q1 2025. The trial, involving 248 patients, aims to reduce liver fibrosis using F351, a drug with anti-fibrotic effects in vitro and in vivo models. Gyre plans to initiate a Phase 2 trial in the U.S. for F351 in MASH-associated fibrosis in 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath